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EC  : Endothelial cell 
FEV1  : Forced expiratory volume in 1 second 
GAPDH  : Glyceraldehyde 3-phosphate dehydrogenase 
HC  : Healthy controls 
H&E  : Hematoxylin and eosin 
HPMEC  : Human pulmonary microvascular endothelial cell 
HUVEC  : Human umbilical vain endothelial cell 
ICS  : Inhaled corticosteroids 
MMA  : Mild-moderate asthmatics 
OCS  : Oral corticosteroids 
PAS  : Periodic acid–Schiff 
RBM  : Reticular basement membrane  
SA  : Severe asthmatics 
TGF  : Transforming growth factor 
VEGF  : Vascular endothelial growth factor  
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ABSTRACT  
Introduction: Activin-A is a pleiotropic cytokine that regulates allergic 
inflammation. Its role in the regulation of angiogenesis, a key feature of airways 
remodelling in asthma, remains unexplored. 
Objectives: Investigate the expression of activin-A in asthma and its effects on 
angiogenesis in vitro. 
Methods: Expression of soluble/immunoreactive activin-A and its receptors was 
measured in serum, bronchoalveolar lavage fluid (BALF) and endobronchial biopsies 
from 16 healthy controls, 19 mild/moderate and 22 severe asthmatics. In vitro activin-
A effects on baseline and VEGF-induced human endothelial cell angiogenesis, 
signalling and cytokine release were compared with BALF concentrations of these 
cytokines in vivo. 
Measurements and Main Results: Activin-A expression was significantly elevated 
in serum, BALF and bronchial tissue of the asthmatics, while expression of its protein 
receptors was reduced. In vitro, activin-A suppressed VEGF-induced endothelial cell 
proliferation and angiogenesis, inducing autocrine production of anti-angiogenic 
soluble (s)VEGFR1 and IL-18, while reducing production of pro-angiogenic 
VEGFR2 and IL-17. In parallel, BALF concentrations of sVEGFR1 and IL-18 were 
significantly reduced in severe asthmatics in vivo and inversely correlated with 
angiogenesis. 
Conclusions: Activin-A is over-expressed and has anti-angiogenic effects in vitro that 
are not propagated in vivo, where reduced basal expression of its receptors is observed 
especially in severe asthma.  
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INTRODUCTION 
Severe asthma is increasingly recognised as a distinct disease entity associated with 
high morbidity and healthcare costs and represents a major unmet therapeutic need 
[1]. In addition to airways inflammation, remodelling changes are implicated in the 
pathogenesis of severe asthma and can lead to irreversible airflow obstruction [2]. 
Local airways angiogenesis is increasingly acknowledged to play a role in the 
pathophysiology of airway remodelling changes associated with asthma [3]. 
Disordered angiogenesis may occur early in life and lead to accelerated lung function 
decline, prolonged symptoms, impaired quality of life and, even, death [3;4]. Thus, 
amelioration of this process represents a likely valid target for therapeutic 
intervention and is indeed already the subject of elaborate research [5;6]. 
Angiogenesis is a multifaceted process regulated by the balance between the 
actions of numerous pro and anti-angiogenic factors [7-12], such that, no single 
mediator can be considered solely responsible [13]. VEGF promotes endothelial cell 
(EC) proliferation and differentiation and represents a key-inducer of bronchial 
angiogenesis in asthma through the activation of its membrane receptors, VEGFR1 
and VEGFR2 [14;15]. Other pro-angiogenic factors, such as IL-17 and IL-13, have 
also been identified [10;16;17]. Among angiogenesis inhibitors, soluble VEGF 
receptor-1 (sVEGFR1), IL-18 and IL-32, exhibit potent potential effects, although, 
their possible roles in the context of severe asthma have not been explored [7-
9;18;19]. Understanding the balance of interactions between pro and anti-angiogenic 
activities in the inflammatory milieu of the severe asthmatic airways remains a 
considerable challenge. 
Activin-A is a pleiotropic cytokine, belonging to the TGF-β superfamily [20]. 
While TGF-β1 signalling occurs via the TβRII, activin-A signals primarily through 
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binding to the activin-A receptor type IIA (Act-RIIA), which results in 
phosphorylation of the type I receptor (termed activin-like kinase [ALK]-4) [20]. 
Downstream signalling occurs via phosphorylation of receptor-regulated Smads (R-
Smads) that translocate to the nucleus to initiate gene transcription [20]. Both TGF-β 
and activin-A signalling pathways have been shown to be activated upon allergen 
provocation in asthma [21;22]. Emerging evidence underscores the potential impact 
of activin-A on the regulation of airway inflammation and remodelling [22-27]. 
Previous studies by our group and others have demonstrated an anti-inflammatory 
role for activin-A in various settings [28-31], while other studies have shown 
opposing effects [23;24]. Interestingly, although the effects of activin-A on airway 
vascularization have never been addressed, investigation of its angiogenic effects on 
other tissues has also produced conflicting results [32-34]. These discrepancies 
highlight the possibility that, although activin-A may be over-expressed in 
inflammation, its end-effects may be diverse or even ablated by modification of its 
signalling in particular inflammatory environments in vivo.  
In the present study, we set out to investigate the expression and possible role of 
activin-A in regulating airways vascularity in severe asthma. We hypothesized that 
activin-A is produced to excess in the asthmatic bronchial mucosa by a variety of 
infiltrating and structural cells, including vascular endothelial cells. We further 
hypothesized that activin-A has the potential to regulate endothelial cell proliferation 
and angiogenesis but that its end effects are influenced by the integrity of its 
signalling pathway and the presence of other locally expressed mediators. To achieve 
this, we investigated the expression and origins of activin-A and its signalling 
molecules in the airways of patients with asthma of varying severity as well as healthy 
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controls. We also examined both the production of activin-A and its interactions with 
other cytokines regulating angiogenesis in cultured human endothelial cells in vitro.  
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METHODS 
Full methodological details are provided in the Methods section in this article’s 
Online Supplement. 
 
Study population 
A total of 57 non-smoking subjects, including 16 non-atopic healthy controls (HC), 
19 patients with persistent mild-moderate (MMA) and 22 patients with persistent 
severe asthma (SA), participated in the study (Table 1). All asthmatic patients had a 
physician confirmed diagnosis and asthma severity was defined according to recent 
GINA and ERS/ATS guidelines [35;36]. Patients had been taking anti-asthmatic 
therapy at a stable dosage for at least for 3 months prior to study enrolment. Subjects 
underwent fiberoptic bronchoscopy with endobronchial biopsy and BAL collection 
at steady state. Serum samples were collected from patients at steady state and if and 
when an exacerbation occurred during a two-year follow up period (n=17), prior to 
the administration of oral corticosteroids (OCS) (see flow-chart in supplement, 
Figure E1). Asthma exacerbations were defined as episodes of severe symptom 
deterioration and elevated rescue medication usage that required the administration 
of systemic corticosteroids or at an elevated dosage for at least three days [37]. Prior 
to participation in the study, all subjects provided informed written consent and the 
protocol was approved by the hospital’s Research Ethics Committee and the Greek 
National Organization for Medicines. All studies were conducted according to the 
principles of the Declaration of Helsinki. More information regarding the study 
population is available in the supplement. 
 
Fiberoptic bronchoscopy and sample collection 
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Bronchoscopy was performed on an outpatient basis, as previously described [38]. 
After inspection of the bronchial tree, lavage was performed and BAL samples with 
a fluid recovery of ≥ 60% were retained for further analysis (HC n=13, MMA n= 12, 
SA n=19), according to the ERS Task Force guidelines regarding measurements of 
acellular components in BAL [39].  
 
Cytokine measurements 
Commercially available ELISA kits were used to determine the concentration of 
human activin-A, IL-17A, IL-18, IL-32, VEGF and sVEGFR1 in the serum, BAL and 
endothelial cell culture supernatants according to the manufacturers’ instructions (see 
supplement).  
 
Tissue staining and measurements 
Paraffin sections 3-4 μm thick were utilised for H&E and immunohistochemical 
staining and 6 μm thick frozen sections for immunofluorescence. Immunostaining for 
activin-A, ALK-4, Act-RIIA and subsequent quantification was performed as 
previously described [22;30;38]. Immunofluorescent staining for cellular markers 
was also performed as preciously described [38]. Blood vessels were identified with 
the vascular endothelial cell marker CD31 (goat polyclonal anti-CD31, sc-1506, 
1:200, Santa Cruz, USA), and the total numbers of vessels divided by the biopsy area 
to determine the numbers of vessels per unit area (mm2) of the sections. Extensive 
methodological information on tissue processing and analysis is presented in the 
online supplement.  
 
Endothelial cell cultures, proliferation and in vitro angiogenesis assays 
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Human umbilical vein (HUVEC) and human pulmonary microvascular (HPMEC) 
endothelial cell lines were purchased from Merck Millipore (Darmstadt, Germany) 
and PromoCell (Heidelberg, Germany), respectively. Their proliferation was 
measured 48h after plating (>90% confluence) using a commercially available kit 
(WST-8, Cayman Chemicals), as previously described [40]. For the in vitro 
angiogenesis assay, the V2A kit (ZHA 4000, TCS Cellworks, Buckingham, UK) was 
employed as previously described [40]. Recombinant human (rh)-IL-13 (10 ng/mL, 
R&D Systems), rh-activin-A (200 ng/mL, R&D Systems) and rh-VEGF (2 ng/mL, 
Biolegend) were applied for 48h at concentrations similar to previously described 
studies [34;41] after performing dose response and kinetic studies (see supplement, 
Figure E2). A human polyclonal anti-activin-A antibody was used for blocking 
activin-A (15 μg/mL, R&D). All experiments were repeated three times in tetraplicate 
wells. The results were expressed as percentages of medium control values. 
 
RNA extraction and Real-Time PCR 
Total RNA was isolated from HUVEC in TRI Reagent (MRC, OH, US) following 
the manufacturer’s instructions (see supplement, Table E1).  
 
Statistical analysis 
Data are expressed as median and interquartile range, unless specified otherwise. 
Comparisons between subject groups were performed using the Kruskal-Wallis one-
way analysis of variance accompanied by Dunn’s post hoc correction. The Wilcoxon 
matched-pair test was applied to compare activin-A expression in the stable state and 
during exacerbation. Correlation coefficients were calculated using the Spearman’s 
rank method. Regarding the in vitro data, comparisons between three or more groups 
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were analyzed by one way ANOVA followed by the Mann-Whitney U test to 
compare specific pairs for significant differences. A statistical software package was 
used for all data analysis and graph preparation (Prism v5; GraphPad, San Diego, CA, 
USA). A p value of ≤ 0.05 was considered significant.  
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RESULTS 
For median values and interquartile ranges please refer to Table 1. 
 
Activin-A is increased in the airway of asthmatics and peaks during asthma 
exacerbations 
Activin-A concentrations were measured in the serum and BAL fluid of asthmatics 
with distinct disease severities. Patients with MMA and SA had significantly elevated 
serum activin-A compared to HC (Figure 1A). In addition, activin-A was 
significantly increased in the BAL fluid of MMA and SA compared to HC (Figure 
1B). Interestingly, activin-A was markedly further increased in the serum of 
asthmatics during exacerbations compared with the steady-state (Figure 1C). No 
associations were found between activin-A levels in the serum, BALF or bronchial 
tissue and the risk of exhibiting an exacerbation among asthma patients (data not 
shown). Still, there was a trend for a negative association between the body mass 
index (BMI) and activin-A levels in the serum and BALF which however did not 
reach statistical significance (see supplement, Figure E3) 
Expression of activin-A immunoreactivity was markedly elevated in epithelial 
and subepithelial infiltrating inflammatory cells in asthmatics (Figure 1D). 
Quantitative analysis revealed that the median number of activin-A immunoreactive 
cells was significantly increased in the bronchial epithelium in MMA and SA, 
compared to HC (Figure 1E). Furthermore, activin-A expression by resident and 
infiltrating cells in the lamina propria was significantly elevated in SA compared to 
both MMA and HC (Figure 1F). No significant differences were observed in the 
serum, BALF or airway expression of activin-A between atopics and non-atopic 
asthmatics (see supplement, Figure E4) or in the severe asthmatics treated or not 
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treated with oral corticosteroids (see supplement, Figure E5). Double 
immunofluorescence coupled with confocal microscopy in severe asthmatics 
revealed that mast cells, neutrophils, macrophages, endothelial and smooth muscle 
cells express activin-A, which in some cases seems to have intranuclear localization 
(Figures 1G to 1J).  
 
Activin-A signalling pathways are dysregulated in severe asthma 
In contrast to activin-A, bronchial mucosal expression of immunoreactivity for its 
receptor proteins was reduced, especially in severe asthmatics. The median number 
of cells expressing Act-RIIA immunoreactivity was significantly reduced in the 
bronchial epithelium and lamina propria in MMA and SA compared to HC (Figure 
2A). ALK-4 expression was significantly reduced in epithelial and subepithelial cells 
only in SA compared to HC (Figure 2B), with intermediate expression in MMA. No 
significant differences were observed in the airway expression of activin-A and its 
receptors ALK-4 and Act-RIIA between atopic and non-atopic asthmatics (see 
supplement, Figure E4) nor in the severe asthmatics treated or not treated with oral 
corticosteroids (see supplement, Figure E5). 
 
Activin-A in the asthmatic bronchial mucosa correlates with angiogenesis 
Evaluation of the vascularity of the bronchial mucosa demonstrated that MMA and 
SA patients had significantly elevated median numbers of blood vessels per unit area 
in the lamina propria compared to HC (Figure 3A). Interestingly, our data revealed a 
strong correlation between the degree of angiogenesis and activin-A expression in 
epithelial (Figure 3B) and subepithelial cells (Figure 3C). In contrast, bronchial 
mucosal expression of both activin-A receptors, ALK-4 and Act-RIIA inversely 
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correlated with angiogenesis (Figures 3D-E and 3F-G, respectively), suggesting that 
activin-A signalling is decreased in patients with prominent angiogenesis. Airways 
angiogenesis inversely correlated with FEV1, and although no correlation was 
observed with activin-A, increased airways expression of ALK-4 and Act-RIIA was 
associated with improved lung function (see supplement, Figure E6). 
 
Activin-A suppresses spontaneous and VEGF-induced proliferation of human 
pulmonary endothelial cells 
Immunofluorescence analysis of biopsies from severe asthmatics revealed that the 
majority of mucosal peribronchial endothelial cells expressed immunoreactivity for 
activin-A (Figure 4A). ALK-4 and Act-RIIA were also expressed, albeit, by fewer 
of the pulmonary EC (Figure 4B and data not shown).  
Corresponding in vitro experiments using HUVEC and, more pertinently, 
HPMEC [42], confirmed that, as in vivo, immunoreactivity for activin-A and its 
receptors was expressed in the resting state by sub-populations of HPMEC (Figure 
4C and 4D) and HUVEC (not shown). To mimic the pro-allergic in vivo setting, we 
exposed HPMEC to IL-13, a critical inflammatory mediator in asthma with an active 
signalling pathway in endothelial cells [43;44]. IL-13 exposure significantly 
increased the mean percentages of HPMEC expressing activin-A, but decreased the 
mean percentages of ALK-4+ and Act-RIIA+ cells (Figure 4D). Moreover, activin-A 
was detectable in culture supernatants of HPMEC at rest and its secretion 
significantly enhanced by IL-13 (Figure 4E). Exposure of endothelial cells to 
exogenous activin-A significantly reduced both spontaneous and VEGF-enhanced 
HPMEC proliferation, even in the presence of the inflammatory cytokine, IL-13 
(Figure 4F). Similar findings were obtained using HUVEC (data not shown). In an 
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opposite approach, we evaluated the effects of activin-A neutralization on HPMEC 
proliferative responses. Blockade of activin-A resulted in enhanced HPMEC 
responses to VEGF and IL-13 (Figure 4F). 
 
Activin-A inhibits VEGF-induced angiogenesis 
To further explore the effects of activin-A on the regulation of human endothelial cell 
responses, we utilized an in vitro model of angiogenesis. In this assay, exogenous 
VEGF strongly promoted spontaneous angiogenesis, reflected by a significant 
elevation of all output parameters investigated, such as the number of junctions and 
tubules, as well as the total tubule length (Figure 5A and 5B). Activin-A did not alter 
spontaneous angiogenesis but significantly inhibited VEGF-induced angiogenesis 
(Figure 5B). Interestingly, activin-A significantly reduced VEGF-enhanced 
angiogenesis also in the presence of IL-13 (Figure 5B), while neutralization of 
activin-A resulted in enhanced angiogenic responses to VEGF and IL-13 (Figure 
5C). 
 
Activin-A regulates the balance of VEGF receptors and induces an anti-
angiogenic cytokine milieu 
Stimulation of HUVEC with activin-A resulted in a significant (approximately 3-
fold) increase in expression of mRNA encoding sVEGFR1 and mVEGFR1, and to 
lesser extent VEGFR2, compared with control (Figure 6A-B). VEGF significantly 
increased expression of mRNA encoding VEGFR2, while it had no discernible effects 
on mRNA encoding sVEGFR1 (Figure 6A and 6C). When employed together, the 
effects of activin-A prevailed over those of VEGF (Figure 6A-C), so that, whereas 
VEGF induced a high VEGFR2/sVGEFR1 mRNA ratio, this was reversed in the 
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presence of activin-A (Figure 6D). Similar findings were observed with the 
VEGFR2/mVGEFR1 ratio (Figure 6E). Consistent with the mRNA data, stimulation 
of endothelial cells with activin-A significantly increased the release of sVEFGR1 
protein into the culture supernatants in the presence or absence of VEGF (Figure 6F). 
No significant differences were observed in VEGFR2 protein levels between the 
groups studied (data not shown). 
Incubation of endothelial cells with activin-A in vitro resulted in significantly 
elevated mean release of IL-18 into culture supernatants, compared with medium 
control, whereas VEGF significantly reduced mean IL-18 release (Figure 6G). In the 
additional presence of activin-A this effect of VEGF was reversed (Figure 6G). In 
contrast, activin-A significantly reduced mean release of the pro-angiogenic cytokine 
IL-17 in medium control and VEGF-treated cells (Figure 6H). IL-32 release by 
human ECs was not altered in the presence of activin-A or VEGF (see supplement, 
Figure E7). 
 
IL-18 and sVEGFR1 are decreased in the BAL and inversely correlate with 
bronchial tissue angiogenesis in severe asthma 
In an effort to translate our findings into the clinical setting, we investigated the 
concentrations of the afore-mentioned mediators in the BALF of patients with asthma 
of varying severity. The median concentration of IL-18 and sVEGFR1 were 
significantly lower in the BAL fluid of SA compared to HC (Figure 7A and 7B). 
Conversely, VEGF was significantly increased in SA (Figure 7C). No significant 
differences were observed in BALF median concentrations of IL-17 and IL-32 
between the groups examined (see supplement, Figure E8). In contrast to VEGF, 
BALF concentrations of IL-18 and sVEGFR1 inversely correlated with the degree of 
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airway angiogenesis (Figure 7D to 7F). Moreover, IL-18 and sVEGFR1 levels in the 
BAL tended to inversely correlate with those of activin-A (see supplement, Figure 
E9). No significant correlations were found between VEGF, IL-18 and sVEGFR1 
and activin-A levels in the serum (data not shown).   
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DISCUSSION 
Our study clearly demonstrates that activin-A is increased in the serum, BAL fluid 
and bronchial tissue in patients with asthma and further increases during 
exacerbations. Our preliminary data further suggest that its mass production is not 
susceptible to systemic glucocorticoid inhibition. The expression of activin-A is more 
prominent in the subepithelium of the bronchial mucosa of severe asthmatics, where 
it is produced by a variety of structural and inflammatory cells, including bronchial 
endothelial cells in a “TH2 high” environment. The hypothesis that endothelial cells 
are a major source of activin-A production in asthma in vivo is supported by our 
observed correlation between airways vascularity (the degree of which was in turn 
associated with more severe disease) and activin-A expression. Bronchial epithelial 
cells also appear to be a potent source. Our hypothesis that activin-A may exert 
regulatory effects on angiogenesis in asthma in vivo is supported by the fact that 
endothelial cells express activin-A receptors, albeit in a potentially attenuated form 
in the more severe patients.  
No significant differences regarding activin-A levels were observed in the serum 
or BALF of MMA and SA patients. It is not uncommon that the expression of certain 
mediators involved in severe asthma and associated airway remodelling processes 
does not differ between severe and mild/moderate asthmatics, as in the case of matrix 
metalloproteinases, eotaxin, IL-5 and IL-13 [45-47], or even in the case of established 
biomarkers, such as sputum eosinophils and FeNO [46;48]. Nevertheless, as in the 
case of IL-13 [47], our findings did reveal a significant increase in the numbers of 
resident and infiltrating cells expressing activin-A in the lamina propria of severe 
asthmatics. The observation that activin-A exerts effects on endothelial cells in the 
airways, even though, it is predominantly expressed by bronchial epithelial cells, 
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corroborates the pleiotropic nature of activin-A in the context of asthma. 
Predominance of expression of a certain cytokine by the bronchial epithelium does 
not preclude a pathogenic role for the corresponding factor in other cell types and 
processes. In fact, several mediators involved in asthma pathophysiology, such as, 
TGF-β [49;50], osteopontin [38;51], pentraxin-3 (PTX3) [52], resistin-like molecule-
β [53], are prominently expressed in the bronchial epithelium and exert effects on 
subepithelial cells. Interestingly, and in agreement with other studies, our findings 
demonstrated that activin-A is also localized in the nucleus of subepithelial cells in 
the bronchial mucosa, possibly reflecting other, yet unidentified, roles for this 
cytokine in gene regulation [54;55]. 
A prominent finding of our study is that activin-A has the ability to suppress 
human pulmonary endothelial cell proliferation and angiogenesis in vitro, even in the 
presence of a robust endothelial cellular activator, such as VEGF. VEGF exerts its 
angiogenic effects in the asthmatic airway through its two main receptors VEGFR1 
and VEGFR2 [14], which have similar structures but divergent functions in vivo [18]. 
We demonstrate here that the anti-angiogenic effects of activin-A may be propagated 
partly through its ability to invert the ratio of VEGFR2/VGEFR1 mRNA expression 
by endothelial cells, thereby modulating VEGF signalling. Furthermore, we show that 
activin-A stimulation has the potential to alter endothelial cell production of cytokines 
that affect angiogenesis, in particular by increasing the secretion of the anti-
angiogenic IL-18 [7;9] while reducing that of the pro-angiogenic IL-17 [10], both at 
baseline and in the presence of VEGF. Finally, we also demonstrate an additional, 
novel biological effect of activin-A on the production of the inhibitory, circulating 
form of the VEGR1 by endothelial cells, through which it may indirectly further 
mitigate VEGF signalling [19].  
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The impact of activin-A on bronchial angiogenesis has not previously been 
explored, although its effects on vascularisation have been investigated in other 
tissues with conflicting results [32-34]. Our data throw considerable light on the 
possible reasons for these conflicting data. The fact that angiogenesis appears to 
proceed in severe asthmatics in the face of elevated expression of activin-A raises the 
possibility that its effects may not be propagated at least partly because of 
modification of its signalling pathway. This hypothesis is supported by our finding 
that, in contrast to activin-A, the expression of its receptors, ALK-4 and Act-RIIA, 
was reduced, at least at the level of reduced immunoreactivity, in the bronchial tissue 
of severe asthmatics. 
It is possible that these changes are brought about by the highly inflammatory 
environment of the bronchial mucosa in asthma. In support of this, we show that 
stimulation with IL-13 markedly reduces the expression of Act-RIIA and, to a lesser 
extent, ALK-4 in human pulmonary endothelial cells. IL-13 is a critical inflammatory 
mediator in asthma with an active signalling pathway in endothelial cells [43;44] and 
the ability to induce VEGF production [16;17] and mediate its effects in vivo [56]. 
Inhibition of activin-A signalling by other inflammatory mediators locally in the 
airways, such as LPS and TNFα, has similarly been previously reported [57]. A 
variety of cytokines with increased expression in the bronchial mucosa of severe 
asthmatics, including VEGF as observed herein and by others [11], may counteract 
the upregulation of angiogenic inhibitors, such as sVEGFR1 and IL-18,  through 
which activin-A partly mediates its effects. Our observation that both sVEGFR1 and 
IL-18 concentrations were decreased in the BAL fluid of severe asthmatics, whereas 
that of VEGF was increased even in the presence of high concentrations of activin-
A, are in agreement with this hypothesis (see Figure 8). Decreased ALK-4 expression 
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has been also reported in the airway epithelium of chronically challenged mice [58], 
suggesting that allergen exposure per se could modify the expression pattern of 
activin-A’s signalling pathway. Although we observed no differences regarding the 
expression of activin-A, ALK4 and Act-RIIA in the lung biopsies from atopic and 
non-atopic asthmatics, the possibility that allergen exposure influences their 
expression cannot be excluded. 
The current study presents certain limitations. In an observational cross-sectional 
study, there is no longitudinal follow-up and it is difficult to pursue specific 
postulated mechanisms of disease, for which longer term studies and/or “models” 
may sometimes be more appropriate. Secondly, the activin-A concentrations used in 
our study for the stimulation of endothelial cell lines, although optimized by 
preliminary in vitro experiments and similar to those used by others, are higher than 
those observed in the BALF and serum of our asthma patients ex vivo. Finally, we did 
not utilize fresh primary bronchial endothelial cells for our in vitro experiments and, 
in the absence of an established cell line based on human peribronchial endothelial 
cells, we have utilized a human pulmonary microvascular endothelial cell line, as the 
most appropriate readily available cell line for studying human lung diseases 
[42;59;60].  
In summary, our studies expand our knowledge of the scope of activities of 
activin-A in asthma, adding potential anti-angiogenic effects to its already versatile 
functions as a cytokine. We also demonstrate the principle, likely applicable to any 
complex, chronic inflammatory process, that over-expression of a cytokine such as 
activin-A in asthma does not inevitably result in the same end effects as observed in 
vitro because of complex, local environmental interactions in vivo. Our findings 
provide the groundwork for future research aiming to better understand these complex 
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interactions in order to evaluate activin-A as a possible target for affecting the course 
angiogenesis in asthma.  
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Figure legends 
Figure 1. Activin-A is increased in asthma. a) Activin-A concentrations in the 
serum and b) BAL fluid at steady state, and c) serum during exacerbation. d) 
Representative microphotographs (x200) demonstrating activin-A expression, as 
indicated (blue arrow: epithelial staining, red arrows: subepithelial staining x400). e-
f) Quantification of activin-A+ cells in the bronchial mucosa. g-j) Confocal 
microscopic images from bronchial tissue of severe asthmatics demonstrating co-
localization (yellow) of activin-A (red) expression by subepithelial cell markers 
(green, x400) and specifically g) mast cells, h) neutrophils, i) macrophages and j) 
smooth muscle cells. Data are presented as median (interquartile range). HC: healthy 
controls, MMA: mild/moderate asthmatics, SA: severe asthmatics, DAPI: 4',6-
diamidino-2-phenylindole, α-SMA: α-smooth muscle actin, * p < 0.05, ** p < 0.01, 
*** p < 0.001 
 
Figure 2. Expression of activin-A receptors Act-RIIA and ALK-4 is markedly 
reduced in severe asthmatics. Representative microphotographs (x200) and 
quantitative analysis of a) Act-RIIA and b) ALK-4 in bronchial biopsy sections, as 
indicated. Data are presented as median (interquartile range). HC: healthy controls, 
MMA: mild/moderate asthmatics, SA: severe asthmatics, * p < 0.05, ** p < 0.01, *** 
p < 0.001 
 
Figure 3. Airway angiogenesis correlates with activin-A expression and is 
associated with reduced tissue expression of ALK-4 and Act-RIIA. a) 
Quantification of airway angiogenesis in all groups. b-c) Correlation of angiogenesis 
with epithelial and subepithelial activin-A expression in all subjects. d-g) Inverse 
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correlations of angiogenesis with epithelial and subepithelial expression of activin-
A’s receptors ALK-4 and Act-RIIA in all subjects, respectively. Data are presented 
as median (interquartile range). HC: healthy controls, MMA: mild/moderate 
asthmatics, SA: severe asthmatics, ** p < 0.01, *** p < 0.001 
 
Figure 4. Activin-A inhibits the proliferation of HPMEC in vitro. Representative 
photomicrographs (x400) demonstrating a) activin-A (red) and b) ALK-4 (red) in 
CD34+ ECs (green) in severe asthmatics. Co-localization is shown in yellow (arrows). 
c) Representative photomicrographs (x200) and d) quantification of 
immunoreactivity for von Willebrand factor (vWF), activin-A, ALK-4, Act-RIIA and 
pSmad2/3 on HPMEC in the presence or absence of rh-IL-13, as indicated. e) Activin-
A concentrations in HPMEC supernatants in the presence (+) or absence (-) of IL-13. 
f) Proliferation of HPMEC, as indicated. Data are presented as mean ± SEM from 
three independent experiments in tetraplicate wells. DAPI: 4',6-diamidino-2-
phenylindole, HPMEC: human pulmonary microvascular endothelial cells, rAct-A: 
recombinant activin-A, aAct-A: anti-activin-A, * p < 0.05, ** p < 0.01, *** p < 0.001 
 
Figure 5. Activin-A inhibits VEGF-induced angiogenesis in vitro. a) 
Representative photomicrographs (x4) showing the formation of endothelial tubular 
structures (black) at day 14, as indicated. Computer-assisted quantification of the 
number of junctions, tubules, and tubule length demonstrating the effects of 
stimulation with b) anti-activin-A neutralizing antibody or Ig control and c) 
recombinant activin-A on VEGF and IL-13 induced angiogenic processes. Data are 
presented as mean ± SEM from six different photomicrographs per parameter and are 
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representative of three independent experiments in tetraplicate wells. * p < 0.05, ** 
p < 0.01, *** p < 0.001 
 
Figure 6. The anti-angiogenic effects of activin-A are associated with enhanced 
sVEGFR1 and decreased VEGFR2. Quantitative real-time PCR analysis of a) 
sVEGFR1, b) mVEGFR1 and c) VEGFR2 mRNA expression by HUVEC relative to 
GAPDH upon stimulation for 96h, as indicated. d) Log ratios of VEGFR2/sVEGFR1 
and e) VEGFR2/mVEGFR1 mRNA expression, as indicated. f) Soluble VEGFR1 
concentrations in culture supernatants. g) IL-18 and h) IL-17 concentrations in culture 
supernatants, as indicated. Data are presented as mean ± SEM from three independent 
experiments in duplicate wells.  * p < 0.05, ** p < 0.01, *** p < 0.001.  
 
Figure 7. BAL fluid IL-18 and sVEGFR1 concentrations inversely correlate with 
airways vascularity in SA. a) Soluble IL-18, b) sVEGFR1 and c) VEGF 
concentrations in the BAL fluid. Correlations of d) IL-18, e) sVEGFR1 and f) VEGF 
with angiogenesis in the airways of all subjects. Data are presented as median 
(interquartile range). HC: healthy controls, MMA: mild/moderate asthmatics, SA: 
severe asthmatics, * p < 0.05, ** p < 0.01 
 
Figure 8. Proposed model for activin-A-mediated inhibition of angiogenesis in 
the airways of asthmatic individuals. In healthy individuals, upon exposure to 
environmental antigens, bronchial epithelial cells release activin-A which signals 
through its receptors on airway endothelial cells and inhibits VEGF-induced 
angiogenesis. This is associated with an enhanced release of the anti-angiogenic 
mediators, IL-18 and VEGFR1. However, in asthmatics, in the presence of 
33 
 
inflammatory cytokines in the airways (such as, IL-13, IL-5, etc) the expression of 
activin-A receptors is decreased and, thus, its signalling pathways are disrupted. As 
an effect, activin-A, although overexpressed in the airways of asthmatics, cannot 
inhibit VEGF-induced angiogenesis or increase IL-18 and VEGFR1 levels.  
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Table 1. Subject characteristics and results of quantification of activin-A, Act-RIIA, 
ALK-4 and airway angiogenesis in all groups examined. Data are depicted as median 
and interquartile range, unless otherwise specified. 
 
Healthy 
Controls 
Mild/Moderate 
Asthmatics 
Severe Asthmatics 
Demographics 
Subjects n 16 19 22 
Age yrs 
46.5 (38.7 – 
56.7) 
43 (38 – 61) 50.5 (39.4 – 59) 
Males/females n 10/6 6/13 3/19 
Asthma duration yrs  NA 30 (2 – 63) 34 (12 – 63) 
BMI 
26.7 (24.4 – 
28.8) 
27.3 (23.4 – 
29.9) 
29.3 (25 – 31.6) 
FEV1 pred (%) 92 (85.3 – 103.1) 82.2 (68 – 89.8)* 67.2 (52.8 – 79.4)† ‡ 
Atopy n 0 11 17 
IgE  33 (19.5 – 43.7) 73 (31 – 168) 120 (63 – 366)† ‡ 
LABA n  16 22 
LTRA n   4 
ICS (mcg/day) § NA 600 ± 55 1800 ± 89 
ΟCS (n, mg/day) # NA NA 12 (9 ± 1)  
Activin-A levels (pg/mL) 
Serum 103 (63-169) 265 (110-367) 206 (123-342) 
BAL 334 (102-391) 517 (370-612) 499 (343-569) 
Airway epithelial cells (% of total epithelial cells) 
Activin-A+  4 (2-19.2) 55 (32-68) 45.5 (25.7-68) 
Act-RIIA+  64 (48-75) 29 (10-38.5) 18 (4-34) 
ALK-4+ 58.5 (43.2-75.5)  51 (42-69.5) 39 (21-49) 
Airway subepithelial cells (per mm2) 
Activin-A+  10 (4-27.1) 140 (56-257) 293 (182-555) 
Act-RIIA+  240 (193-305) 137 (18.5-175.5) 44 (0-132) 
ALK-4+  203 (139-333) 120 (69-160) 89 (12-170) 
Angiogenesis (ves/mm2) 80.5 (59.7-99.7) 158 (98-220) 207.5 (151.3-300.5) 
NA: Not applicable, BAL: bronchoalveolar lavage fluid, BMI: Body mass index, 
FEV1: Forced expiratory volume in 1 second, LABA: Long-acting β-2 agonists, ICS: 
Inhaled corticosteroids, ΟCS: Oral corticosteroids 
*: p < 0.5 compared to HC, †: p < 0.001 compared to HC, ‡: p < 0.01 compared to 
mild/moderate asthmatics 
§: Beclometasone dipropionate CFC equivalent dosage, mean ± SEM 
#: Prednisolone equivalent dosage, mean ± SEM 
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